Evidence map›Paper›PMID 40301031›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Efficacy of Combined Dabrafenib and Trametinib Therapy in BRAFV600E Mutant Intrahepatic Cholangiocarcinoma with a Neurofibromatosis Type 2 Mutation.

Jumpei Yoshida, Keiji Sugiyama, Seira Owaki, Takumi Ito, Yuhei Yamaguchi, Ryosuke Emi, Yuki Sako, Mariko Satoh, Riku Ino, Kyoko Kato and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jumpei YoshidaDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Keiji SugiyamaDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Seira OwakiDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Takumi ItoDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Yuhei YamaguchiDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Ryosuke EmiDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Yuki SakoDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Mariko SatohDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Riku InoDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Kyoko KatoDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.
Kazuhiro ShiraishiDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Japan.
Masaaki ShimadaDepartment of Gastroenterology, NHO Nagoya Medical Center, Japan.
Hiroyoshi HattoriDepartment of Clinical Genetics, NHO Nagoya Medical Center, Japan.
Chiyoe KitagawaDepartment of Medical Oncology, NHO Nagoya Medical Center, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a 41-year-old woman with BRAFV600E-mutated intrahepatic cholangiocarcinoma and a concurrent loss of function in NF2. The patient had a large liver tumor, multiple lymph nodes, and metastases to the lungs and pleura. She underwent six cycles of gemcitabine, cisplatin, and durvalumab but was refractory to this treatment. Comprehensive genomic profiling revealed a BRAFV600E mutation along with a loss of function in NF2. The patient was treated with a combination of oral dabrafenib and trametinib therapy. After two months, imaging showed reduced pleural effusion, tumor shrinkage, symptom resolution, and improved performance status, without significant side effects.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCholangiocarcinomaMutationProto-Oncogene Proteins B-rafPyridonesPyrimidinonesAdultFemaleHumansImidazolesOximesTreatment OutcomeBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibcholangiocarcinomadabrafenibneurofibromatosis type 2trametinibv-raf murine sarcoma viral oncogene homolog B1

Identifiers

PMID40301031
PMCPMC12659954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.